BofA analyst Tim Anderson raised the firm’s price target on Amylyx (AMLX) to $14 from $10 and keeps a Buy rating on the shares after the company reported Q2 results and reiterated it has a cash runway to the end of 2026. The firm’s higher target reflects changes in estimates, including a lower operating expense forecast in 2026, and updating its base valuation year to 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx Pharmaceuticals Halts ORION Program for AMX0035
- Amylyx to discontinue ORION program of AMX0035
- Amylyx Pharmaceuticals Advances Phase 3 Study on Avexitide for Post-Bariatric Hypoglycemia
- Amylyx Pharmaceuticals’ Promising Earnings Call Highlights
- Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide’s Advancements